Sanofi acquires Translate Bio for mRNA therapeutic development
WEBSep 24, 2021 · Sanofi acquired all outstanding shares of Translate Bio for $38 per share in cash, representing a total equity value of approximately $3.2 billion on a fully diluted basis. Translate Bio is an mRNA therapeutics company developing a new class of medicines to treat or prevent debilitating and life-threatening diseases.
Peptides: a promising alternative to opioids for chronic pain relief
WEBOct 25, 2021 · A novel peptide for pain relief. The researchers developed a novel peptide molecule that could prevent endocytosis to reduce the hyperactivity of these pain neurons and thereby minimise pain perception. “This novel peptide molecule is a lipidated endocytic dileucine sequence found in the human CD4 protein known to bind to the AP2 complex at ...
Antibody-drug conjugates payloads: then, now and next
WEBOct 4, 2023 · This approach – immune-stimulating antibody conjugates (ISACs) – uses a payload that stimulates the innate and adaptive immune responses, recruiting tumour-fighting T cells. 15 ISACs use small immuno-agonist molecules conjugated to the antibody to boost the immune response while minimising toxicity. Where traditional ADCs kill …
Interactive 3D model of SARS-CoV-2 surface released - Drug …
WEBSep 25, 2020 · A new interactive three-dimensional (3D) map of SARS-CoV-2, the virus causing the COVID-19 pandemic, has been released by researchers. The model is free for scientists who wish to use it to aid in the search for a COVID-19 treatment or vaccine. According to the creators, from Fusion Animation, the model was made by assembling together parts ...
The next generation of cancer immunotherapies: the IL-2 pathway
WEBSep 17, 2020 · An important development was the production of recombinant IL-2, which allowed easier access to larger quantities of IL-2 5 and was first used in an oncology clinical trial in 1985. 6 The half-life of IL-2 was determined to be seven minutes, so administration every eight hours was needed to keep therapeutic IL-2 in the patients’ bodies. 6 Although tumour regression was observed in patients ...
Exploring alternatives to animal testing in drug discovery
WEBJul 6, 2023 · Overall, there are several alternatives to animal testing that can be used in pre-clinical research. These alternatives offer many advantages, including ethical considerations, reduced costs and improved accuracy. In vitro and in silico methods, 3D tissue engineering and organ-on-a-chip are some …
Articles - Drug Target Review
WEB25 September 2024 | By Stefanie Flückiger-Mangual (TOLREMO Therapeutics) Drug resistance is the leading cause of poor clinical outcomes for cancer patients undergoing targeted therapies. While current treatments are designed to inhibit targets along established oncogenic signalling cascades, a new, exciting approach is …
Recent trends in upstream bioprocessing and major challenges in …
WEBSep 17, 2019 · Figure 2: Optimisation areas and parameters in upstream processing. Stable cell lines – a major challenge for upstream development. Establishing the stability of those cell lines being used for antibody production forms an important part of upstream development. Stability conventionally indicates the antibody- production capability of cells.
Realising the promise of DNA vaccines and enabling genetic …
WEBApr 5, 2022 · The success of messenger RNA (mRNA) vaccines against SARS-CoV-2 has renewed interest in the broader development of nucleic acid-based vaccine technologies. Both mRNA and DNA vaccines deliver nucleic acid sequences that encode viral or tumour antigens designed to stimulate the production of neutralising antibodies and T cells.
High-throughput screening as a method for discovering new drugs
WEBJun 4, 2020 · High-throughput screening is a common method of identifying lead compounds for drug development. The most common targets are enzymes – catalytic proteins that perform chemical reactions in the cell. In this article, Matthew Lloyd discusses the opportunities and challenges associated with …